Real-World Results from 2,249 Copper-64 DOTATATE PET Scans for Neuroendocrine Tumors | Research

The takeaway

In the largest study of routine copper-64 DOTATATE PET/CT use, the peptide-based scan detected tumor progression that standard CT missed in over 20% of cases where disease worsened.

21.5% PET-only progression
In cases where tumors worsened, over 1 in 5 were detected only by the peptide PET scan, not by standard CT

What the researchers found

Across 2,249 consecutive clinical copper-64 DOTATATE PET/CT scans in 1,290 neuroendocrine tumor patients:

- **Most common indication**: Monitoring without clinical progression (31.3% of scans)

- **Image results**: No disease in 29.7%, stable disease in 25.9%, progression in 20.5%

- **PET-only progression**: In 99 of 461 cases with progression (21.5%), disease worsening was detected by PET but not by CT

- **Initial staging** accounted for 9.8% and **PRRT selection** for 4.2% of scans

- **16.5% of scans** were for indications not even defined in current appropriate use criteria

The high detection rate of progression in the monitoring group — particularly PET-only progression — supports upgrading this indication from "may be appropriate" to "appropriate" in guidelines.

Why it matters

Somatostatin receptor PET/CT using peptide-based tracers is the gold standard for imaging neuroendocrine tumors, but guidelines about when to use it are still evolving. This is the largest real-world study of copper-64 DOTATATE, and it provides the evidence base to expand appropriate use criteria. The finding that PET detected progression invisible to CT in over 20% of worsening cases is clinically important — it means some patients would have their disease progression missed without the peptide-based scan.

How the study worked

Retrospective analysis of all clinical routine copper-64 DOTATATE PET/CT scans performed at Copenhagen University Hospital-Rigshospitalet from April 2018 to May 2022. Referral text and image reports for all 2,249 scans were reviewed. Each scan's indication was classified according to established appropriate use criteria (AUC). Image results were categorized as no disease, stable, progression, or other.

What this study cannot tell us

This is a single-center, retrospective study from a specialized neuroendocrine tumor center, which may not reflect practice patterns at general hospitals. Referral bias toward more complex cases could inflate the rate of detected progression. The study did not compare copper-64 DOTATATE directly with gallium-68 DOTATATE or FDG-PET. Clinical outcomes based on scan findings were not reported.

How to read the evidence

This is a large retrospective real-world study from a single specialized center. While it provides valuable practice data from 2,249 scans, the retrospective design and single-center origin limit the ability to draw definitive conclusions about imaging guidelines.

When this study was published

Published in 2024, this is a current study reflecting contemporary clinical practice with copper-64 DOTATATE PET/CT.

The bigger picture

Peptide-based PET imaging using somatostatin analogs (like DOTATATE labeled with gallium-68 or copper-64) has transformed neuroendocrine tumor management. This study demonstrates the clinical value of these scans at scale and provides data to support broader use. The copper-64 label offers potential advantages over gallium-68 including longer half-life and potentially better image quality. Real-world studies like this are essential for developing evidence-based imaging guidelines.

Questions still open

Does detecting PET-only progression lead to earlier treatment changes and improved patient outcomes?
How does copper-64 DOTATATE compare to gallium-68 DOTATATE in detecting progression in routine clinical use?
Should monitoring scans be recommended at standardized intervals for all neuroendocrine tumor patients?

Common questions

What is DOTATATE PET and why is it important for neuroendocrine tumors?

DOTATATE is a peptide that binds to somatostatin receptors, which are abundant on the surface of neuroendocrine tumors. When labeled with a radioactive isotope (like copper-64) and injected, it travels through the bloodstream and concentrates in tumors, making them visible on a PET scan. This is more sensitive than regular CT for detecting neuroendocrine tumors and their spread.

Why was the PET scan able to find tumors that CT missed?

CT scans detect tumors by their physical shape and size. DOTATATE PET detects tumors by their biology — specifically, the somatostatin receptors on their surface. Small tumors or early progression may not yet be large enough to appear on CT but already express enough receptors to light up on PET. This is why 21.5% of progression cases were only visible on the peptide PET scan.

Read the original research

Routine Use of [64Cu]Cu-DOTATATE PET/CT in a Neuroendocrine Tumor Center: Referral Patterns and Image Results of 2,249 Consecutive Scans.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 65(11), 1754-1761

View on PubMed ↗Publisher’s paper ↗

Citation

Carlsen, Esben Andreas; Loft, Mathias; Johnbeck, Camilla Bardram; Knigge, Ulrich; Langer, Seppo W; Mortensen, Jann; Enevoldsen, Lotte; Oturai, Peter; Kjaer, Andreas. (2024). Routine Use of [64Cu]Cu-DOTATATE PET/CT in a Neuroendocrine Tumor Center: Referral Patterns and Image Results of 2,249 Consecutive Scans.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 65(11), 1754-1761. https://doi.org/10.2967/jnumed.124.267939